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ABSTRACT
Breast cancer is one of the most common malignancies in women. It continues to
be a major burden and cause of death among women worldwide. Molecular oncology is
now one of the most promising fields that may contribute considerably to diagnosis of
breast cancer and its metastases addressing major problems with early detection, accurate
staging, and monitoring of breast cancer patients. The overall objective of these
feasibility studies was to contribute to improved diagnosis, prognosis, and prediction of
breast cancer disease through the development of reagents and protocols for the use of
molecular biological advances and the assessment of the relative potential of these
diagnostic procedures for the detection and quantification of multiple specific mRNA
tumor markers. Newest molecular technologies such as real-time quantitative TaqMan
RT-PCR assays, microarray analyses, and production of “in-house” arrays were included
in the study. Tissue, blood, and bone marrow samples were obtained from surgeries of
confirmed and suspected breast cancer patients. TaqMan assays were performed for six
mRNA markers: MAGE 3, HER2/NEU, MGB 1, CK 20, PSA, and HPR. Low-density
nylon arrays with 265 immobilized genes included in cell to cell interactions were used
for microarray analyses. Three highly overexpressed genes from microarray analyses and
negative controls were selected for custom spotting on nylon membranes to produce “inhouse” arrays. It was concluded that TaqMan assays can be easily designed and
implemented for the screening of a large number of clinical specimens when including
carefully selected controls, high purity RNA from samples, and a set of mRNA markers.
Custom arrays can be produced incorporating multiple selected mRNA markers. It is
suggested that the initial screening of biological samples could be done by microarray
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analyses and individual positive samples could be confirmed by additional tests using
real-time quantitative TaqMan assays.

v

INTRODUCTION
Breast cancer is the formation of a malignant tumor that has developed from cells
in the breast.
Breast Cancer Current Statistics
Breast cancer continues to be one of the most common cancers and a major cause
of death among women worldwide. According to the current statistics of the Centers for
Disease Control and Prevention, breast cancer is the most common cancer in women in the
United States (excluding skin cancer) accounting for 32 percent of all female cancers.
Breast cancer is responsible for 18 percent of cancer deaths in women and is second only
to lung cancer. The National Cancer Institute estimates that about 1 in 8 women in the
United States (approximately 13.3 percent) will develop breast cancer during her lifetime.
This estimate is based on cancer rates from 1997 through 1999 (1). The American Cancer
Society estimates that in 2003 approximately 211,300 new invasive cases of breast cancer
will be diagnosed among women in the United States (3,800 of those cases will be
diagnosed in Louisiana). An estimated 39,800 women will die from breast cancer (700
women will die in Louisiana). It is estimated that 1,300 men will be diagnosed and 400
men will die of breast cancer during 2003 (2).
Breast Cancer Types
Each breast has 15 to 20 sections called lobes, which have many smaller sections
called lobules. The lobes and lobules are connected by thin tubes, called ducts (Figure1).
The most common type of breast cancer is ductal cancer. It is found in the cells of the
ducts. Cancer that starts in lobes or lobules is called lobular cancer. It is more often found
in both breasts than other types of breast cancer. Cancers also are classified as non-
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invasive (in situ) and invasive (infiltrating). The term in situ refers to cancer that has not
spread past the area where it initially developed. Invasive breast cancer has a tendency to
spread (metastasize) to other tissues of the breast and/or other regions of the body. A less
common type of breast cancer is inflammatory breast cancer characterized by general
inflammation of the breast. Other rare types of breast cancer are medullary carcinoma (an
invasive breast cancer that forms a distinct boundary between tumor tissue and normal
tissue), mucinous carcinoma (formed by the mucus-producing cancer cells), tubular
carcinoma, etc. (3).

Figure 1: The structure of the female breast

Historical Overview
While the incidence of breast cancer as well as the recovery rate continues to rise,
breast cancer is hardly a new affliction (4-8). The recorded history of breast cancer traces
back thousands of years. It is no surprise that from the dawn of history doctors have
written about cancer. Incidents of breast cancer have been documented back to the early
Egyptians when the popular treatment was cautery of the diseased tissue. Surgery was
practiced but it was an extremely radical treatment considering there was no anesthesia or
antisepsis available.
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The oldest description of cancer (although the term cancer was not used) was
discovered in Egypt and dates back to approximately 1600 B.C. The Edwin Smith Papyrus
describes 8 cases of tumors or ulcers of the breast that were treated by cauterization, with a
tool called “the fire drill”. The writing says about the disease, “There is no treatment”.
The origin of the word cancer is credited to the Greek physician Hippocrates (460370 B.C.), the "Father of Medicine." Hippocrates used the terms carcinos and carcinoma to
describe non-ulcer forming and ulcer-forming tumors. In Greek these words refer to a crab,
most likely applied to the disease because the finger-like spreading projections from a
cancer called to mind the shape of a crab. Carcinoma is the most common type of cancer.
According to the doctrines of the Greek physician Caudius Galen (130-200 AD),
whose works on physiology and anatomy dominated medical thought until the Middle
Ages, melancholia was the chief factor in the development of breast cancer. Special diets
were the recommended treatment. However, other treatments included exorcism and the
use of topical applications which were seldom preferred by patients.
During the Renaissance, Andreas Vesalius recommended mastectomy as well as
ligatures (sutures) to control the bleeding rather than cautery. Recognition that breast
cancer could and did spread to the regional auxiliary nodes was first recognized by the
physician LeDran (1685-1770). Dr. LeDran was likely the first to associate poor prognosis
with the spread of breast cancer to the lymph nodes.
The famous Scottish surgeon John Hunter (1728-1793) suggested that some
cancers might be cured by surgery and described how the surgeon might decide which
cancers to operate on. If the tumor had not invaded nearby tissue and was “moveable”, he
said, “There is no impropriety in removing it”.
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During the mid 1800’s, surgeons first began to keep detailed records of breast
cancer. Those statistics indicate that even those treated by mastectomy had a high rate of
recurrence within eight years—especially when the glands or lymph nodes were affected.
Nevertheless, the common treatment was to remove the breast and the surrounding glands
in an effort to stave off any further tumor development.
In 1894 William Roentgen discovered X-rays. This paramount discovery shed light
on the detection of many diseases as well as breast cancer. Some years later, in 1913,
Albert Solomon, a pathologist in berlin, produced images of 3,000 gross mastectomy
specimens.

He

observed

black

spots

at

the

centers

of

breast

carcinomas

(microcalcifications).
Between the 1930’s and the 1950’s treatment and detection improvements were
noticeable. This was the time when Stafford Warren (Rochester memorial Hospital, New
York) developed a stereoscopic system for tumor identification. Also, doctors started
classifying the stage and progression of breast cancer. In 1949 Raul Leborgne (Uruguay)
emphasized breast compression for identification of calcifications. In 1940s-1950s breast
self-examinations were advocated.
In 1960 Dr. Robert Egan (Houston) adapted high-resolution industrial film for
mammography, allowing simple and reproducible mammograms with improved image
detail. And in 1963 the first randomized controlled trial of screening by the Health
Insurance Plan of New York found that mammography reduced the 5-year breast cancer
mortality rate by 30 percent. Major improvements in mammography equipment, such as
reduced radiation dosage, digital imaging, and computer-aided diagnosis, improved
detection of breast cancer.
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Breast Cancer Risk Factors
Every woman is at risk for developing breast cancer. Several relatively strong risk
factors for breast cancer that affect large proportions of the general population have been
known for some time. However, the vast majority of breast cancer cases occur in women
who have no identifiable risk factors other than their gender (9).
The “established” risk factors for breast cancer are female gender, age, previous
breast cancer, benign breast disease, hereditary factors (family history of breast cancer),
early age at menarche, late age at menopause, late age at first full-term pregnancy,
postmenopausal obesity, low physical activity, race/ethnicity and high-dose exposure to
ionizing radiation early in life.
The “speculated” risk factors for breast cancer include never having been pregnant,
having only one pregnancy rather than many, not breast feeding after pregnancy, use of
postmenopausal

estrogen

replacement

therapy

or

postmenopausal

hormone

(estrogen/progestin) replacement therapy, use of oral contraceptives, certain specific
dietary practices (high intake of fat and low intakes of fiber, fruits, and vegetables, low
intake of phytoestrogens), alcohol consumption, tobacco smoking, and abortion.
Although men can and do develop breast cancer, the disease is 100 times more
likely to occur in a woman than in a man (10). Women are at a higher risk of breast cancer
because they have much more breast tissue than men do. Also, estrogen promotes the
development of breast cancer.
The risk of breast cancer is higher in middle-aged and elderly women than in young
women (10; 11). This risk increases as a woman ages, rising sharply after the age of 40. In
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the United States, more than three-fourths of all breast cancers occur in women aged 50 or
older.
A woman who has previously had breast cancer has a three- to four-fold increased
risk of developing a new cancer in the other breast. Women who have had benign breast
problems are also at increased risk but to a lesser extent (12; 13). The risk of breast cancer
is higher among women who have a close blood relative (mother, sister, or daughter) who
have had the disease. The increase in risk is especially high if the relative developed breast
cancer before the age of 50 or in both breasts (14). However, most women who get breast
cancer (approximately 80 percent) have no such family history of the disease (15). The
effect of family history on breast cancer risk is believed to be due primarily to genetic
factors. As much as 5–10 percent of all breast cancer cases are attributable to specific
inherited single-gene mutations, and many other cases have some genetic component. The
evidence from individual families in which breast cancer occurs very frequently and from
large epidemiological studies has shown that some women have a familial predisposition
to breast cancer. The evidence includes the pedigree of Broca’s family (16). He was a
famous French surgeon (1824-1880), and in his family tree (comprising over five
generations) 10 out of 24 women died of breast cancer.
Epidemiological studies have shown that in women with a family history of breast
cancer, the risk of breast cancer is increased two- to threefold. Studies have also shown
that there are families in which breast cancer risk is inherited in an autosomal-dominant
fashion (‘hereditary breast cancer’). Recently, it has been shown that germline mutations in
the BRCA1 and BRCA2 genes account for a large proportion of cases of hereditary breast
cancer (17). Histopathological findings and careful autopsy examinations have played a
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major role in the recognition of many familial cancer syndromes (18). In addition to
mutations in the BRCA1 and BRCA2 genes, there are as yet unidentified genetic defects
that predispose to breast cancer development (19), and additional studies may help in
identifying these genes in the future.
Women who reach menarche at a relatively early age (12 or younger) and those
who reach menopause at a relatively late age (55 or older) are slightly more likely than
other women to develop breast cancer (13). These relationships are believed to be mediated
through estrogen production (20). During the reproductive years, a woman’s body
produces high levels of estrogen. Women who start to menstruate at an early age and/or
reach menopause at a late age are exposed to high levels of estrogen for more years than
are women who have a late menarche or early menopause.
Age at first pregnancy is another aspect of reproductive history that is associated
with breast cancer risk. Women who have their first full-term pregnancy at a relatively
early age have a lower risk of breast cancer than those who never have children or those
who have their first child relatively late in life (13). The biologic basis for this relationship
is not entirely clear.
Obesity has been consistently associated with an increased risk of breast cancer
among postmenopausal women (21; 22). This relationship may be mediated again by
estrogen production. Fat cells produce some estrogen and obese postmenopausal women,
therefore, tend to have higher blood estrogen levels than lean women.
Studies have consistently shown that the risk of breast cancer is lower among physically
active premenopausal women than among sedentary women (23; 24). Physical activity
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during adolescence may be especially protective, and the effect of physical activity may be
strongest among women who have at least one full-term pregnancy.
Studies of racial/ethnic characteristics of breast cancer reveal that non-Hispanic
white, Hawaiian, and black women have the highest levels of breast cancer risk. Other
Asian/Pacific Islander groups and Hispanic women have lower levels of risk. Some of the
lowest levels of risk occur among Korean and Vietnamese women (25).
Women who were exposed to high doses of radiation, especially during
adolescence, have an increased risk of breast cancer. This association has been observed
both among atomic bomb survivors and among women who received high-dose radiation
for medical purposes (26; 27).
Parity (having children) and the age of the woman at the birth of her first offspring
are other endogenous hormonal factors that influence breast cancer. Women who have
never had children (nulliparous) are at greater risk for the development of breast cancer
than women who have had children (parous). There is also consistent evidence that first
pregnancy completed before age 30-35 lowers risk of breast cancer, and that first full-term
pregnancy after age 30-35 raises risk. More limited evidence suggests that women who
have many pregnancies may be less likely to develop breast cancer than those who have
only one pregnancy (13).
Some studies have shown that women who breast-feed their babies may be less
likely to develop breast cancer than those who have children but do not breast-feed (28).
Other studies, however, indicate that there may be little or no relationship between breast
feeding and breast cancer risk. If breast-feeding does protect against breast cancer, it may
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do so by delaying the resumption of ovulation (with its accompanying high estrogen
levels) after pregnancy.
The long-term (more than five years) use of postmenopausal estrogen therapy
(ERT) or combined estrogen/progestin hormone replacement therapy (HRT) may be
associated with an increase in breast cancer risk (29).
The associations between the use of oral contraceptives and breast cancer have
been studied. Many studies attempting to link oral contraceptives with increased breast
cancer have been inconclusive (30). But these studies have shown that oral contraceptives
do not have a large effect on breast cancer risk. Whether they have a small effect on risk is
less clear.
A possible relationship between breast cancer and diet has been suggested due to
the variation of breast cancer in societies with different national diets (the high rates in
Western industrialized nations and the low rates in Asia, Latin America, and Africa). A
comparison of vegetarian versus meat-eating women produced inconclusive results. No
relation between breast cancer risk and total fat, saturated fat, or cholesterol was found.
Some of the effects that were once attributed to dietary fat intake were probably due to
obesity (which is often linked with high fat intake) rather than to fat intake per se. And the
effects of fiber, fruits, and vegetables now appear to be small, at best. Diets high in fruits
and vegetables and low in fat and calories are healthful for many reasons, and they may
indirectly reduce the risk of breast cancer by helping to prevent obesity.
Plant substances called isoflavones (sometimes referred to as phytoestrogens) are
most commonly found in soy products. It has been speculated that these substances may be
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protective against breast cancer (31). They appear to have effects similar to those of
estrogen in some tissues while antagonizing the effects of estrogen in other tissues.
A positive, but modest association between alcohol use and breast cancer risk is
seen in most studies (32; 33). There is also some evidence that cigarette smoking may be
associated with a small increase in breast cancer risk. However, epidemiological studies
have variably shown positive, inverse, or null associations (34). Among women who have
already been diagnosed with breast cancer, smoking may be associated with an increased
risk that the cancer will progress more rapidly. In some studies, premature termination of
pregnancy appears to increase breast cancer risk (35). In incomplete pregnancy, the breast
is exposed only to the high estrogen levels of early pregnancy and thus may be responsible
for the increased risk seen in these women. However, some other studies found no
association between abortions and increased risk of breast cancer (36).
Stages of Breast Cancer
The staging systems currently in use for breast cancer are based on the clinical size
and extent of invasion of the primary tumor (T), the clinical absence or presence of
palpable axillary lymph nodes and evidence of their local invasion (N), together with the
clinical and imaging evidence of distant metastases (M). This is then translated into the
TNM classification which has been subdivided into Stage 0 called carcinoma in situ
(lobular carcinoma in situ (LCIS) and ductal carcinoma in situ (DCIS) and four broad
categories by the Union Internationale Centre Cancer (UICC), which are the following.
Stage I – early stage breast cancer where the tumor is less than 2 cm across and
hasn't spread beyond the breast.
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Stage II – early stage breast cancer where the tumor is either less than 2 cm across
and has spread to the lymph nodes under the arm; or the tumor is between 2 and 5 cm (with
or without spread to the lymph nodes under the arm); or the tumor is greater than 5 cm and
hasn't spread outside the breast.
Stage III – locally advanced breast cancer where the tumor is greater than 5 cm
across and has spread to the lymph nodes under the arm; or the cancer is extensive in the
underarm lymph nodes; or the cancer has spread to lymph nodes near the breastbone or to
other tissues near the breast.
Stage IV – metastatic breast cancer where the cancer has spread outside the breast
to other organs in the body.
The Past and the Future of Breast Cancer Detection
Increased breast cancer awareness with breast self-examinations and major
improvements in routine breast cancer screening had a paramount effect on early detection
of breast cancer. Improvements in conventional mammography (an x-ray technique to
visualize the internal structure of the breast) such as the low radiation dosage, enhanced
image quality, development of statistical techniques for computer-assisted interpretation of
images, long-distance, electronic image transmission technologies (telemammography
/teleradiology) for clinical consultations, and improved image-guided techniques to assist
with breast biopsies (the removal of cells or tissues for examination under a microscope)
continue to lower the morbidity and mortality of breast cancer. The support of research on
technologies that do not use x-rays and are not used for routine breast cancer screening,
such as magnetic resonance imaging (MRI), ultrasound, and breast-specific positron
emission tomography (PET) may play a considerable role in further improvements of
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breast cancer early detection. In most cases, the earlier breast cancer is detected, the better
the survival rate. Today mammography is the best available method to detect breast cancer
in its earliest, most treatable stage - an average of 1.7 years before the woman can feel the
lump. Generally, treatment is most effective before the disease spreads. When breast
cancer is diagnosed at a local stage, the 5-year survival rate is greater than 90%. This rate
decreases to less than 50% when the disease has spread to the lymph nodes and less than
20% when it has spread to distant organ sites.
Despite recent progress in early detection and surgical therapy, the mortality due to
breast cancer has changed little over the past decades, primarily because the occult
dissemination of cancer cells can occur at an early stage of carcinogenesis. Occult
dissemination of tumor cells in patients with operable cancer can subsequently lead to
formation of metastasis, yet it is usually missed by conventional tumor staging. The
success of routine mammography screening for breast cancer is that it involves
increasingly more patients with small primary tumors formerly thought to have an overall
excellent prognosis. Yet, only approximately two thirds of these patients actually have this
favorable prognosis, while the remaining third develops metastatic disease. Thus, there is
emerging evidence that tumor cells can disseminate into secondary organs at an earlier
stage of primary tumor development than appreciated by current risk classifications. There
are several challenges that must be addressed in an effort to continue to lower the mortality
associated with this disease.
Molecular oncology is currently one of the most promising fields, which may
address the major problems with early detection and accurate staging of women with breast
cancer. The advent of highly sensitive, molecular techniques, such as the polymerase chain
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reaction (PCR), enables the detection of circulating tumor cells and small metastasis at the
molecular level. PCR-based assays are used for the detection of tumor cells in lymph
nodes, resection margins, bone marrow and blood. Methods to detect metastatic disease
and circulating tumor cells at a molecular level are of two types: those that detect somatic
events such as point mutations or chromosomal rearrangements, and those that detect
expression of tumor specific mRNAs. Both methods have been applied for the detection of
many different tumor types (37). The main limitation of the first method is that not all
tumors contain mutations suitable for PCR amplification. For the second method to work,
the molecular marker must be transcriptionally elevated in malignant cells and not in the
surrounding cells or tissue.
Gene amplification/overexpression is a common event in the progression of human
cancers, and amplified genes have been shown to serve as molecular markers and have
diagnostic, prognostic and therapeutic relevance. Currently, molecular markers offer the
unique opportunity to identify occult metastases in early stage cancer patients not
otherwise detected with conventional staging techniques. The completion of the human
genome as well as an enormous amount of information on the transcriptional activities in
cancer cells enable the selection of specific markers for the detection of cancer cells. The
ideal prognostic marker is one that clearly delineates a particular prognostic group, is
100% specific, highly sensitive, inexpensive and easy to perform on a small quantity of
fresh or fixed tissue. No such marker exists but a number of potential prognostic markers
have been extensively investigated. Multiple proteins have been found to be specifically
overexpressed in certain types of tumors (i.e. Her2neu, PSA, p53, pRB, melanoma
antigens, etc.). Detection and quantification of potential tumor markers using sensitive
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molecular methods could assist in the early diagnosis of cancer disease as well as in the
efficacy of anti-cancer therapy. The clinical application of molecular markers in the
diagnosis, staging, and management of breast cancer continues to expand. The molecular
detection of circulating tumor cells and micrometastases may help develop new prognostic
markers. Extensive work by various groups has been done on minimal residual disease
(MRD) detection in blood, bone marrow and lymph nodes in cancer patients with different
types of cancer. In the past 10 years, numerous investigators have attempted the detection
of occult tumor cells in malignancies using the highly sensitive reverse transcriptase
polymerase chain reaction (RT-PCR) technique. This is a particularly sensitive technique
for the purpose of detecting occult breast cancer cells in the blood, bone marrow, and
lymph nodes of breast cancer patients (38-40). It is simple, rapid, and semi-automatic, and
is an alternative method to fluorescence in situ hybridization and immunochemistry. RTPCR has produced sensitivity levels of 1 tumor cell in 1,000,000 normal cells. It can detect
micrometastases based on amplification of mRNA expressed exclusively in the cancer
cells of interest or in significantly larger amounts in cancer versus non-cancer cells
localized to the lymph node, other distant organs or circulating in the blood. RT-PCR may
be a powerful tool for large randomized, prospective cooperative group trials and support
future tumor-marker based biological and gene-therapy approaches. The labor intensive
and time consuming pathological investigations can be minimized or substantially assisted
using automated RT-PCR assays. These assays, in the vast majority, have been directed
against tissue specific markers. In most studies on prostatic carcinoma, RT-PCR was able
to specifically detect prostatic tissue specific markers in the peripheral blood, bone marrow
and lymph nodes of patients with localized and metastatic disease. Melanoma related
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transcripts were detected by RT-PCR in the peripheral blood, bone marrow and lymph
nodes of patients with localized and advanced tumors. Many authors have shown a
statistically significant correlation between RT-PCR positivity and a poorer outcome in
both melanoma and prostatic carcinoma. In breast carcinoma, all markers that have been
extensively tested were shown to be non-specific.
The presence or absence of axillary lymph node metastasis is still the single most
reliable predictor of the final outcome in breast cancer and the primary determinant for the
use of systemic therapy in patients with newly diagnosed cancer confined to the breast.
Although these patients are considered as potentially curable, a substantial number of them
develop recurrent carcinoma and die of their disease in 5 to 10 years, including nearly 30%
of patients with negative axillary lymph nodes (41). As mentioned earlier, occult
dissemination of tumor cells in the patients with operable cancer can subsequently lead to
formation of metastases, yet it is missed by conventional tumor staging with
histopathology and immunohistochemistry in the lymph nodes. The blood and bone
marrow are not currently routinely examined for tumor cells in women with breast cancer.
However, it is likely, that if these sites were routinely assessed, tumor cells would be
identified. Ultimately, knowledge of tumor cells’ presence in the blood or bone marrow
may impact the survival of breast cancer patients via earlier detection and initiation of
adjuvant therapy. A reliable RT-PCR assay has not been developed for breast cancer. The
targeted tumor markers for detection by RT-PCR in breast cancer patients have not been
identified as in melanoma. In addition, because of the extreme sensitivity of RT-PCR
technique, an accepted cut-off value that defines tumor presence or absence has not been
established. However, it is widely accepted that the detection of mRNA tumor markers and
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well-defined experimental protocols can greatly improve the sensitivity, specificity, and
reliability of the RT-PCR assay system.
Breast tumors are composed of a heterogeneous collection of cells with differing
levels of individual gene expression. Therefore, the predominant cell type or its metastasis
may not express a particular marker (42; 43). Therefore, it is believed that multimarker
approaches with a panel of tumor-specific mRNA markers may improve the sensitivity and
specificity for the detection of tumor cells over single marker assays in breast cancer
patients. Furthermore, tumors continuously evolve genetically over time in response to
host pressures and treatment interventions, which suggests that single marker testing may
not be able to effectively monitor cancer progression. Simultaneous detection of such
markers by newly developed methodologies such as real-time quantitative RT-PCR will
enable the accurate monitoring of the level of mRNA markers as well as the precise
comparison to known internal mRNA standards.
Lymph node metastatic involvement is arbitrarily subdivided into micro- and
macrometastases, usually according to the size of the tumor deposits, with the cut-off point
ranging from 0.2 to 2.0 mm (44; 45). Serial sectioning and immunohistochemistry
appeared to increase the detection rate by 9-33%. A definite survival disadvantage was
noted for patients with such occult metastases. The use of extensive serial sectioning and
immunohistochemistry on all axillary lymph nodes is too expensive and labor-intensive to
be practical. Sentinel lymph node (SLN) is the first lymph node in the axillary basin to
receive metastases from the primary breast cancer if they have occurred. The concept of
SLN was introduced by Cabanas (46). The SLN accurately predicts the pathology of the
remaining axillary basin allowing a focused pathologic analysis of it (47). If the SLN does
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not contain tumor, the chance of tumor in the remaining axillary lymph nodes is less than
1%. Therefore, patients without tumor in the SLN can avoid unnecessary axillary lymph
node dissections (ALND). A SLN biopsy in comparison to an ALND has significantly less
morbidity in terms of lymphedema, numbness to the arm, and decreased range of motion.
The assessment of the SLN at the time of initial diagnosis of breast cancer may improve
upon the current staging molecular method - multiple mRNA marker RT-PCR analysis,
which would identify the sub-group of patients with metastases in the SLN but thought to
be free of disease by conventional pathologic examinations. Therefore, the analysis of
micrometastatic cells opens a new avenue by which to assess the molecular determinants
of both early tumor cell dissemination and subsequent outgrowth into overt metastases.
Tumor cell detection in the bone marrow is being regarded increasingly as a
clinically relevant prognostic factor for breast cancer. Many studies suggest that tumor-cell
shedding already occurs during the early stages of breast cancer and have demonstrated a
significant correlation between tumor cell detection in the bone marrow and decreased
disease-free and overall survival (48-50). Studies have shown that breast cancer patients
may harbor bone marrow metastases alone or in conjunction with axillary metastases.
These studies suggest that the tumor status of the bone marrow may be a better prognostic
indicator than the axillary lymph node status (51). Since the primary breast tumor can
spread by both the lymphatic and hematogenous route, it is possible that patients may have
metastases to the bone marrow and not the axillary lymph nodes. It is now clear that bone
marrow is one of the most prominent secondary organs to receive disseminated tumor cells
and is an important determinant for micrometastatic organ involvement due to its ease of
accessibility and normal physiological absence of epithelial cells. Bone marrow aspirates
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can be easily obtained from breast cancer patients at the time of surgery. The technical
feasibility and the potential prognostic significance of bone marrow metastases makes
assessing this site for tumor spread clinically important. Therefore, the multiple-marker
RT-PCR assays may be used to molecularly stage the bone marrow detecting
micrometastases not identified with conventional pathology.
Increased accuracy in staging breast cancer patient disease and initiation of earlier
therapeutic interventions unequivocally are beneficial consequences of technological
advancements that identify high-risk patients early in their disease course. Blood testing
provides a minimally invasive method to evaluate the presence of circulating tumor cells
that may serve as indicators for assessing risk of recurrence. Current imaging techniques
used to identify breast cancer metastases often require a significant tumor burden for
detection. Furthermore, the procurement of sufficient tissue to confirm the diagnosis can
be associated with significant morbidity and cost depending on the size and location of the
lesion as mentioned previously. Therefore, the utility of detecting tumor cells in the blood
potentially offers a practical, safe, and cost-effective alternative to traditional methods of
diagnosing disease recurrence and/or systemic spreading. In prostate and colon cancer,
prostate specific antigen (PSA) and carcinoembrionic antigen (CEA) which are measured
in the blood have served as a tremendous tool in the management of these cancer types
respectively. To date, well-characterized molecular tumor markers to detect occult breast
cancer cells in the blood are limited. There is no breast cancer tumor marker that can be
measured in the blood, used for screening, serve as prognostic indicator, measure response
to therapy, or signal early recurrence of the disease. The advantage of tumor marker
detection in the blood is that it can be serially measured throughout the course of the
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disease, unlike lymph node and bone marrow biopsies. The development of a multiplemarker RT-PCR assay to detect micrometastases in the blood would considerably improve
staging at the time of diagnosis of breast cancer patients enabling the early institution of
the therapy that could lead to improved survival in patients that have disease relapse. A
reliable breast cancer tumor marker that could be measured in the blood would potentially
detect the disease before it becomes clinically visible on screening mammography or
palpable on clinical exam. The increased levels of the tumor marker could lead to more
frequent monitoring, further testing of patients, or earlier biopsy of suspicious lesions seen
on mammography. It could also be used for postoperative monitoring, for determining the
response to chemotherapy, and for prolonged post-treatment monitoring. The development
of a multiple-marker RT-PCR assay that would be able to detect micrometastases in the
blood identifying circulating tumor markers would have the potential to be used in above
mentioned situations.
New prognostic markers can be tested in this very efficient way. If the study proves
successful, the markers can be adopted for routine use either alone or, more probably, in
combination with standard clinical assessment. It is believed that a number of molecular
markers will make the transition from the laboratory to the clinic over the coming decades
with the ultimate benefit being better prognostication and therapy of breast cancer patients.
Tumor Markers
A tumor marker is defined as a substance present/overexpressed in or produced by
a tumor (tumor-derived), or the host (tumor-associated), that can be used for differentiating
neoplastic from normal tissue. Tumor markers are found in cells, tissues, and body fluids
such as cerebrospinal fluid, serum, plasma, and milk. The ideal marker would be useful in
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diagnosis, staging and prognosis of cancer, provide an estimation of tumor burden, and
serve for monitoring effects of therapy, detecting recurrence, localization of tumors, and
screening in general populations (52). Most (if not all) tumor markers do not fit the ideal
profile. The reason for this can be the relative lack of sensitivity and specificity of the
available tests. It should be noted, that virtually any protein or chemical has the potential to
be a tumor marker. As tumor cells grow and multiply, some of their substances increase in
tumor tissues and/or leak into the bloodstream or other fluids. Depending upon the tumor
marker, it can be measured in blood, urine, stool or tissue. Some widely used tumor
markers include: AFP, Her2/Neu, beta-HCG, CA 19-9, CA 27.29 (CA 15-3), CA 125,
CEA, and PSA. Some tumor markers are associated with many types of cancer; others,
with as few as one. Some tumor markers are always elevated in specific cancers; most are
less predictable. However, no tumor marker is specific for cancer and most are found in
low levels in healthy persons, or can be associated with non-neoplastic diseases as well as
cancer. Tumor markers have been categorized as enzymes, isoenzymes, hormones, specific
cell membrane proteins, oncofetal and cell-specific antigens, carbohydrate epitopes,
oncogene products, genetic changes, etc. There are only a handful of well-established
tumor markers that are being used by physicians. Many other potential markers are still
being researched. There are many studies now that are trying to find new genes involved in
signaling molecules or proteins that “tell” cells to proliferate, invade or metastasize.
•

AFP and CEA: There are two common oncofetal antigens, alpha-fetoprotein

(AFP) and carcinoembryonic antigen (CEA). The oncofetal antigens are so named because
they are normally produced during embryonic development and decrease soon after birth.
Cancer cells tend to dedifferentiate, or revert to a more immature tissue and begin to
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produce fetal antigens again. Oncofetal antigens are very non-specific and expressed by a
wide number of cancer types. However, they are used both to monitor a patient's progress
and their response to treatment over time. CEA is a cell surface glycoprotein and it is a
marker for colorectal, gastrointestinal, lung, and breast carcinomas (53). CEA is most
useful in monitoring therapy (as declining levels correlate with tumor burden) and has
utility in detecting recurrence of colorectal cancer. High CEA levels in breast cancer do not
correlate with grade of tumor but are useful for monitoring therapy and detecting
recurrence. AFP is a marker for hepatocellular and germ cell (nonseminoma) carcinoma.
For hepatocellular carcinoma (HCC), the sensitivity of AFP is 98% and the specificity is
65%, making it the most useful marker for HCC (54).
•

Cancer antigen (CA) 27.29 is elevated in breast carcinoma, ovarian and

lung cancer, in normal pregnancy (1st trimester), benign breast disease, cirrhosis and
hepatitis (55). For recurrent breast carcinoma, CA 27.29 has a sensitivity of ~57% and a
specificity of ~87% (56). It lacks the required sensitivity and specificity for routine
detection of breast cancer and does not discriminate patients with early carcinoma from
those with benign breast disease. CA 27.29 is associated with the early detection of
recurrent breast carcinoma.
•

HER-2/neu is an oncogene-encoded growth factor receptor (homologue of

epidermal growth factor (EGF) receptor), also known as c-erbB-2. It is overexpressed in
breast cancers as a result of HER 2 proto-oncogene amplification. It is measured in the
tissue from a biopsy either by immunological assays of the protein or PCR. The presence
of HER-2/neu is generally associated with a more aggressive growth and poorer prognosis
for breast and ovarian cancer (57; 58). It can also help to determine treatment options,
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predicting an enhanced survival benefit from the Her 2-targeted therapy (reviewed by
Horton, 2002 (59), Herceptin (trastuzumab), a monoclonal antibody that can block the
protein receptor and decrease cancer growth. It may also predict for resistance to some
conventional therapies.
•

Prostate specific antigen (PSA) is the most valuable tumor marker for the

diagnosisand management of prostate cancer in terms of high specificity and utility (60),
but it is now widely accepted that PSA is also present in many nonprostatic sources (61).
PSA is a kallikrein-like serine protease first described in seminal plasma (62) and later
found in prostatic tissue (63) and to a minor extent in milk (64) and amnionic fluid (65). It
is a product of epithelial cells of the prostate and is secreted into the seminal fluid. The
measurement of circulating PSA levels combined with digital rectal exam is recommended
annually for all men over age 50. In addition to its use in screening, PSA is frequently used
to monitor treatment of prostate cancer. Other factors affect the PSA level besides cancer.
Older men tend to have a higher PSA normally. Also men with benign prostatic
hypertrophy (BPH) have higher levels.
•

Estrogen receptor (ER) and progesterone receptor (PR): In both pre- and

postmenopausal women, levels of steroid receptors ER and PR can predict which women
are likely to benefit from hormone treatment. Measurements of ER and PR are
recommended to use in the diagnosis, prognosis, and treatment planning for women with
breast cancer. ER gives an indication of responsiveness to therapy. Tissue from a biopsy is
used to measure the estrogen receptor. Most breast cancers in post-menopausal women are
ER-positive, meaning that they require estrogen to grow. These ER positive breast cancers
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are less aggressive than ER negative breast cancers, which are found generally in premenopausal women.
•

P53 is a tumor suppressor gene that is mutated or changed in more than 50

percent of tumors. Studying p53 as a tumor marker helped researchers understand how
tumors form, but measuring p53 levels in cancer patients has not been shown to predict
differences in survival or quality of life. p53 was indicated as responsible for tamoxifen
resistance in breast cancer suggesting that it can interfere in treatment response (66).
•

Cathepsin-D: High levels of this lysosomal enzyme may indicate breast

cancer. There is not enough information to recommend using cathepsin-D levels to make
treatment decisions for patients with primary or metastatic breast cancer and especially to
diagnose the disease but studies have shown its association with reduced disease-free and
overall survival of breast cancer patients (67).
Researchers continue working on specific molecular pathways involved in
oncogenesis, tumor response, tumor progression, etc. to discover new molecular markers
that can have a potential to be routinely used in medical practices of breast cancer.
Laboratory techniques for the study of potential prognostic markers are rapidly developing
at both the gene and protein level. Most techniques now allow the analysis of fresh or
archival tissue. Some of the newly discovered markers are markers involved in cell cycle
dysregulation (cyclin D1, p16INK4a, p14ARF), tumor invasiveness (VEGF, factor VIII
related antigen, Cox-2), stromal-breast epithelium interactions (uPA and related proteins,
E-cadherin, b1 integrin), etc. The documented list of potential breast cancer markers is
expanding every day promising valuable discoveries of new markers and their use in
clinical settings.
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Microarrays
Survival rates of breast cancer improved during the 1900’s. They are steadily
increasing now probably as a result of earlier detection, better staging and improved
treatment. It is thought that the recurrence and mortality rate was high due to poor early
detection techniques. According to the American Cancer Society, mortality rates of breast
cancer declined during the past decade with the largest decreases in younger women (68).
These somewhat encouraging trends are primarily associated with improved screening
techniques and the subsequent increase in diagnosis at an early stage when most cancers
are more successfully treated. Unfortunately, most current therapies have limited efficacy
in curing late-stage disease. Therefore, there continues to be a need to develop new
approaches to diagnose cancer early in its clinical course, more efficiently treat its
advanced stages, predict tumor’s response to therapy, and ultimately prevent cancer
disease. A better understanding of how certain genes and their encoded proteins contribute
to disease onset and tumor progression and how they influence the response of patients to
therapies would be the only way to accomplish these goals. Our era of genetic, biological,
and biochemical innovations gives prominent opportunities to address these questions
uncovering molecular basis of cancer. DNA microarrays are one of the most promising and
powerful technologies in this field becoming a major tool in biomedical area and reshaping
molecular biology. Partial sequence data for thousands of genes have been generated due
to the human genome project’s large-scale sequencing efforts (69; 70). The roles these
genes play in various biological processes have yet to be elucidated. Defining gene
expression profiles, i.e. comparing patterns of expression in different tissues and
developmental stages, in normal and disease states, or in distinct in vitro conditions, is a
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big step toward understanding these roles. RT-PCR, RNase protection assays, and
Northern blot analysis can accomplish the above mentioned goals but these methods focus
on only a few genes at a time. Using microarrays, a single hybridization experiment can
generate an expression profile for hundreds-thousands of genes at once. The ability to
analyse the expression level of thousands of genes in a single assay using DNA
microarrays is transforming the way we do research (71; 72).
The history of microarrays began 25 years ago with the Southern blot, which
introduced the basic technique of anchoring nucleic acids to a solid support for analysis by
hybridization. A DNA microarray is an orderly arrangement of known or unknown DNA
samples attached to a solid support. Each DNA spot on the microarray is usually less than
200 µM in diameter and an entire array typically contains thousands of spots. Many
different design formats are possible (73). The samples attached to the solid support can be
small oligonucleotides, cDNAs or genomic sequences. RNA is isolated from samples,
reverse transcribed into cDNA and labeled. Then it is hybridized on a microarray and
visualized by different techniques.
The range of microarray technology applications is already enormous. While geneexpression profiling is currently the dominant microarray application, microarrays are also
increasingly being used in pharmacogenomics and molecular diagnostics research. The
development of DNA microarrays (or “DNA chips”) in conjunction with human genome
studies has promise to be used in development of a new taxonomy of cancer (74),
including major insights into the genesis, progression, prognosis, and response to therapy
on the basis of gene expression profiles. Genome-wide expression profiling of disease
states opens up a new window for discovery of molecular disease markers and clinical
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monitoring of patients. Major refinements of the technology underlying DNA libraries,
PCR, and hybridization have come together in the development of DNA microarrays.
Currently available DNA microarrays are carefully designed to include genes that
are of interest to researchers in breast cancer field. The use of DNA array techniques now
allows for the simultaneous analysis of the mRNA expression levels of thousands of genes
in mammary tumor cell lines and breast tumors to address different aspects concerning
breast cancer. Using DNA microarrays researchers have attempted to identify clusters of
genes not recognized by the currently available pathological techniques (75), to elucidate
gene expression patterns and survival of breast cancer patients (76), to investigate DNA
copy-number variations in breast cancer cell lines and tumors (77), to examine in vivo
molecular events of breast cancer progression (78), to determine the global impact of gene
copy number variation and reveal amplified novel genes (79), and predict breast cancer
response to therapy (80). There are many other studies that used DNA microarrays to
reveal questions of breast cancer phenomenon but it is impossible to refer to them all in
this chapter. It is becoming clear that continued advancements in the comprehensive
analysis of protein products in conjunction with already confined methods of measurement
of mRNA expression may ultimately uncover the molecular basis of different cancers as
well as breast cancer shedding light on uncountable questions about this problematic
disease.
Objectives of the Project
The overall objective of this research was to contribute to improved diagnosis,
prognosis, and outcome prediction of breast cancer disease through the use of molecular
biological advances in the detection and quantification of multiple mRNA tumor markers.
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Our hypothesis is that the use of well-developed real-time PCR technique will improve the
detection of cancer cells. In addition, the use of real-time PCR in conjunction with
molecular profiling of cancers through the use of DNA microarrays should ultimately
provide a complete suite of molecular tools for the detection as well as characterization of
breast metastatic tumors.
The first goal of this project was to develop and evaluate RT-PCR assays based on
fluorescent TaqMan methodology for the early detection and quantification of multiple
mRNA tumor markers in the blood, bone marrow and lymph nodes of breast cancer
patients. The use of automated, real-time PCR allows for the detection as well as
quantification of the relative levels of multiple tumor mRNAs in comparison to invariable
“housekeeping” mRNAs. This work is a direct continuation of previous work performed
by Dr. Peter Bostick (81-84). In initial studies, Dr. Bostick and colleagues showed the
potential of detecting specific mRNA markers by conventional RT-PCR and Southern Blot
analyses of breast cancer samples obtained from sentinel lymph nodes and blood. Initial
markers included carcinoembryonic antigen (CEA), cytokeratin 19 (CK 19), CK 20,
gastrointestinal tumor-associated antigen 733.2 (GA 733.2) and mucin-1 (MUC-1). CEA,
CK 19, and MUC-1 have been efficiently detected by immunohistochemistry, however,
detection of these mRNAs had no diagnostic value as mRNA markers for the detection of
micrometastases by the RT-PCR assay, because they were expressed in relatively large
amounts in both the blood and lymph nodes of individuals without cancer. Data about
CK20 were inconclusive and additional experiments were warranted to establish whether
CK20 could be used as a diagnostic mRNA tumor marker (81). The levels of expression of
mRNA tumor markers C-Met, beta1

4GalNAc-T, and P97 were also compared. Whereas
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all three tumor markers were expressed in 43% of histopathologically tumor-free sentinel
nodes, the mRNA levels were significantly higher in patients with a family or prior history
of breast cancer, infiltrating lobular carcinoma, estrogen receptor-negative tumor, or a
higher Bloom-Richardson score. It was concluded that the multiple-marker RT-PCR and
Southern blot assays improved the occult metastases detection in the sentinel node when
compared to conventional hematoxylin and eosin staining and immunohistochemistry
analysis. Expression of all 3 tumor mRNA markers in the sentinel node correlated with
poor prognostic clinico-pathologic factors (82). In melanoma studies, Dr Bostick and
colleagues compared detection of occult metastases in the sentinel node of melanoma
patients by the hematoxylin and eosin staining and immunohistochemistry to detection of
metastases by the multiple-mRNA marker RT-PCR assay. The levels of MAGE 3, MART1, and tyrosinase mRNA detected by RT-PCR were correlated with hematoxylin and eosin
staining and immunohistochemistry assay results, standard prognostic factors, and diseasefree survival. Patients with histopathologically melanoma-free sentinel nodes who were
multiple-mRNA marker positive were at increased risk of recurrence, while patients who
were multiple-mRNA marker positive with histopathologically proven metastases in the
sentinel node were at greatest risk of disease relapse, concluding that hematoxylin and
eosin staining and immunohistochemistry underestimate the true incidence of melanoma
metastases. Multiple-mRNA marker expression in the sentinel node more accurately
reflected melanoma micrometastases and was also a more powerful predictor of disease
relapse than the hematoxylin and eosin staining and immunohistochemistry alone (83). In
another multiple-marker melanoma RT-PCR assay, the number of RT-PCR markers
detected in blood was an independent prediction factor of disease recurrence significantly
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predicting disease recurrence in 2, 3, and 4 years of follow-up (84). Molecular detection of
circulating tumor cells, especially as multi-mRNA marker approach, has significant
prognostic value in determining early disease recurrence and might be useful for stratifying
patients for adjuvant therapy. Newer molecular methodologies such as real-time
quantitative TaqMan RT-PCR and cDNA microarrays have been used in these feasibility
studies for assessing the relative potential of diagnostic procedures for the detection of
mRNA tumor markers in breast cancer patient samples.
The following mRNA tumor markers, some of which were used also by Dr.
Bostick, were selected for multi-marker TaqMan analysis: (I) MAGE 3 (melanoma antigen
3); (II) HER2/NEU (human epidermal growth factor receptor 2); (III) MGB 1
(mammoglobin 1); (IV) CK 20 (cytokeratin 20); (V) PSA (prostate specific antigen); and
(VI) HPR (heparanase). The set of markers was selected for multi-marker assay on the
basis of the available published data of expression and specificity of each marker in
primary and metastatic tumors.
MAGE (melanoma antigen) proteins are normal tissue antigens compartmentalized
in testicular cells that play an important role in the early phase of spermatogenesis.
Demethylation induces MAGE antigens in cells, suggesting that MAGE genes are
important developmentally regulated genes under methylation control. Thus, genetic
instability in cells causing loss of this methylating control could result in the preferential
expression of MAGE genes in cancer cells. MAGE genes are preferentially expressed in
many different cancers and detected at both the mRNA and protein levels (recognized by
autologous cytolytic T lymphocytes (CTL). MAGE 3 gene is a member of MAGE gene
family of tumor antigens expressed in many tumors of several types, such as melanoma
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(85), ovarian carcinoma (86), hepatocellular carcinoma (87), head and neck squamous
carcinoma (88), lung carcinoma (89) and breast carcinoma (90), but not in normal tissues
except testes.
The connection of HER 2 to breast cancer outcome was noted relatively long ago
(91). As mentioned earlier, in breast cancer, HER 2 amplification/overexpression
correlates with earlier relapse, shorter disease free- and overall survival predicting for a
poor clinical outcome (91; 57; 58). HER 2 is considered to be a clinically important
molecule and testing for HER 2 abnormalities is already part of routine patient assessment
in many parts of the world. Immunohistochemistry (IHC) and fluorescence in situ
hybridization (FISH) are the most common HER 2 tests used and they guide breast cancer
therapy. They show a high level of concordance, but there is currently no gold standard for
HER 2 testing. The review by Dowsett et al (92) summarizes different assays used for
HER 2 testing discussing their advantages and disadvantages. HER 2 testing approaches
based on RT-PCR are very promising for the routine detection and quantification of this
oncogene expression for primary and metastatic breast cancer diagnosis as well as for
patient monitoring (93; 94). A well-developed and validated RT-PCR assay can be a major
tool for HER 2 testing with defining cut-off values and other standards for the assay.
Mammoglobin (MGB) is a member of the uteroglobin gene family. It is
homologous to a family of secreted proteins that includes rat prostatic steroid-binding
protein subunit C3, human Clara cell 10-kilodalton protein, and rabbit uteroglobin.
Mammoglobin is a relatively recently discovered gene but it has already shown promise
for breast cancer detection. Its expression is limited to the adult mammary epithelium and
it is frequently upregulated in human breast cancer cell lines and primary (95; 96) as well
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as metastatic breast cancer (97). Mammoglobin could be a potential serum marker for
breast cancer diagnosis because it is secreted and is specific to breast tissue.
Cytokeratines (CK), which comprise a multigene family of 20 related polypeptides,
are constituents of the intermediate filaments of epithelial cells, in which they are
expressed in various combinations depending on the epithelial type and the degree of
differentiation. CK 20 is essentially confined to gastrointestinal epithelia, the urothelium
and Merkel cells of epidermis. Sparse CK 20 positive epithelial cells have been noted in
the thymus, bronchus, gall bladder, and prostate gland. CK 20 is expressed in endometrial
(98) and hepatocellular carcinoma (99) tumors but not in the endometrium of patients with
benign diseases or in the blood cells.
As discussed earlier, PSA is a product of epithelial cells of the prostate secreted
into seminal fluid. For some time it was believed that PSA was exclusively expressed in
the prostate and that PSA in the circulation must be prostatic in origin. This has been the
basis for the use of PSA as a tumor marker for prostate cancer and the detection of this
cancer by measuring circulating PSA levels (100; 101). As mentioned before, later it
became apparent that PSA is expressed in nonprostatic tissues. Also, since PSA was
originally identified in the prostate, it has long been assumed that women, lacking a
prostate, would have no circulating PSA. However, with the advent of highly sensitive
assays it has become clear that there are low but detectable levels of PSA in the circulation
of women (102). PSA expression has also been reported in a wide variety of tumors. It has
been detected immunocytochemically in many primary and metastatic melanomas (103), in
primary ovarian carcinoma (104), etc. Many of the studies on extraprostatic PSA were
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inspired by reports that PSA could be detected in breast tumors and in serum of patients
with breast cancer (105; 106).
Heparanase (HPR) is an enzyme expressed by various cells such as platelets,
leukocytes, endothelial cells and smooth muscle cells. It is an endoglycosidase (heparan
sulfate-specific endo-beta-D-glucuronidase) that cleaves heparan sulfates (HS). Heparan
sulfate proteoglycans (HSPGs) play a key role in the self-assembly and barrier properties
of basement membranes and extracellular matrices. Hence, cleavage of heparan sulfate
(HS) affects the integrity and functional state of tissues and thereby fundamental normal
and pathological phenomena involving cell migration and response to changes in the
extracellular microenvironment. The heparanase mRNA and protein are preferentially
expressed in metastatic cell lines and human tumor tissues (107; 108). Enhanced
heparanase expression correlates with increased chance of tumor metastases with tumor
vascularity and poor prognosis of cancer patients (109-111).
The next objective was to focus on the use of low-density DNA arrays containing
cell interaction genes for discovering additional tumor markers. This molecular detection
technology would help to identify multiple tumor associated mRNAs overexpressed in
breast cancer patients in a short time in contrast to time-consuming other different
techniques. It was also anticipated that custom made microarrays could be made to include
the newly discovered and promising markers. For the initial microarray feasibility studies
it was decided to use Atlas Human Cell Interaction array from Clontech, a nylon cDNA
array with 265 immobilized genes on it. Cell interaction molecules such as cell adhesion
proteins, extracellular matrix proteins, proteases, etc. play key roles in mediating cell-cell,
cell-tissue and cell-extracellular matrix interactions and are involved in the normal
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processes of cell growth, division, differentiation, migration, as well as apoptosis. These
genes are also important in many diseases and pathophysiological processes, including
tumor invasion and metastasis, rheumatoid arthritis, cardiovascular disorders, wound
healing, inflammation, and some central nervous diseases. Considerable research has been
done to discover the particular role these proteins play in cancer diseases (112-116). The
list of cell interaction molecules that could serve as potential tumor markers for early
diagnosis of tumors and their metastases is continuing to expand.
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MATERIALS AND METHODS
Sample Acquisition, Storage, and Identification
A limited number of tissue, bone marrow and blood samples were obtained via
collaboration with surgeon oncologist Dr. Peter Bostick and the Baton Rouge General
Hospital. Samples were stored at –80°C after arrival at LSU. RNA was isolated
immediately upon arrival from a portion of the blood samples. The remaining blood
samples were aliquoted into 2ml cryo vials and stored at –80°C. Large tissue samples were
fragmented into smaller samples for ease of storage and application of RNA extraction
procedures and stored at –80°C. Bone marrow samples were aliquoted into smaller
samples within cryo tubes for future manipulations. The list of the samples stored in the
GeneLab freeze, is shown in Table 1. All the samples were obtained from Dr. Bostick’s
surgeries of confirmed or suspected breast cancer patients.

Table 1. List of specimens received at LSU School of Veterinary Medicine
Tissue samples
5062801Tln
00716247Tln
5061542Tln
00657403Tbts
00716247Tbtm
0Tun
5057331Tbtm
00497241Tbtm
05071355Tbtm
05065155Tun

Blood samples
5062801BD
506322BD
5061542BD
657403BD
05065155BD
5057331BD
8/02/00BD
00408233BD
05077954BD
42578906BD

Bone marrow samples
5057331BMl
713328BMl
713328BMr
313163BMr
5057331BMr
05062801BMl
05062801BMr
5061542BMr
5056311BMl
053145BMr
5056311BMr
5056242BMl
053145BMl
5056242BMr
323496BMr
323496BMl
313163BMl
5053504BMr
05063173BMr
05063173BMl
42578906BMr
42578906BMl
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Samples are identified by a number assigned by the Baton Rouge General Hospital,
which relates to each patient. An upper case T denotes tissue samples, ln denotes lymph
node samples, un is for unidentified samples, bts is for breast tissue, btm is for breast
tumor. An upper case BM denotes bone marrow samples, l is for left and r is for right
aspirates. An upper case BD is for blood samples. For example, bone marrow sample
number 713328 right is identified as 713328BMr.
Table 2 includes the list of samples from patients confirmed to have metastatic
breast cancer.
Table 2. Samples of known origin
Sample number

Histological type of cancer

Sample types

5056242

infiltrating ductal carcinoma

bone marrow

313163

infiltrating ductal carcinoma

bone marrow

5056311

infiltrating ductal carcinoma

bone marrow

713328

bone marrow

05057331

intraductal and infiltrating carcinoma
(mucinous type)
poorly differentiated mammary carcinoma

tissue, blood, bone marrow

5062801

infiltrating ductal carcinoma

tissue, blood, bone marrow

5061542

infiltrating ductal carcinoma

tissue, blood, bone marrow

506322

infiltrating ductal carcinoma

blood
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RNA Extraction
Total RNA was isolated from 0.65 cm cubes of tissue samples, from 0.25 ml blood
and bone marrow samples using Absolutely RNA RT-PCR Miniprep Kit from Stratagene
(La Jolla, California). The Absolutely RNA system simplifies the traditional guanidine
thiocyanate method by using a silica-based matrix in a spin-cup format. Following lysis
and homogenization of the clinical samples with Lysis Buffer-β-ME mixture, homogenates
were passed through Prefilter Spin Cups by centrifugation at maximum speed to remove
particulates and much of the DNA contamination. The filtrates were mixed with 70%
ethanol, transferred to Fiber-Matrix Spin Cups (RNA binding spin cups) and spun. The
bound RNA was washed with Law-Salt Wash Buffer and DNase treated by DNase solution
(contained DNase Digestion buffer and RNase-Free DNase I). After multiple washes with
High-Salt and Low-Salt Wash Buffers, RNA was eluted from the spin cups by Elution
Buffer (a low ionic strength buffer). RNA in the Elution buffer was stored at –80°C for
future use.
RT-PCR Assays
The Real-Time Quantitative One-Step RT-PCR TaqMan assays were performed on
the Perkin Elmer ABI PRISM 7700 Sequence Detection System equipment (Applied
Biosystems, Foster City, California), which provides product verification with the highest
stringency and sensitivity permitting continuous automated reading of fluorescence
intensities during PCR. Signal production is directly proportional to the hybridization of a
fluorescent probe, which serves to authenticate the PCR product as well as quantify its
relative amount in comparison to known internal controls (GAPDH, 18S, etc.). A total of
six mRNA markers were tested. Those were: MAGE 3 (melanoma antigen E 3), HER
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2/NEU (human epidermal growth factor receptor 2), MGB 1 (mammoglobin 1), CK 20
(cytokeratin 20), PSA (prostate specific antigen), and HPR (heparanase). Dilutions of RNA
samples from a cell line were used to construct standard curves for target genes and
endogenous reference (GAPDH or 18S). RNA from negative breast cancer cell line
Hs578Bst (American Type Culture Collection, Manassas, Virginia) was used as a
calibrator. Primers and probes were chosen using Primer Express software (Applied
Biosystems). Probes were labeled at the 5’ end with the reporter molecule 6carboxyfluorescein (FAM) and at the 3’ end with the quencher 6-carboxytetramethylrhodamine (TAMRA) (Applied Biosystems) (Table 3).
Table 3. Primer and probe sequences of each marker gene for real-time PCR amplification
Gene

GenBank
accession
number

Primer or
Probe

Sequence

MAGE 3

U03735

Forward
Reverse
Probe

GGTGAGGAGGCAAGGTTCTG
TCTGCTCAAGAGGCATGATGA
ACTGGCAGATCTTCTCCTTCAGTGCTCCT

HER2/NEU

X03363

Forward
Reverse
Probe

AGTGTGCACCGGCACAGA
TTGTGAGCGATGAGCACGTA
AGCCTGTCCTTCCTGCAGGATATCCAG

MGB1

AF015224

Forward
Reverse
Probe

CAAGACAATCAATCCACAAGTGTCT
AACACCTCAACATTGCTCAGAGTT
CTTCTTCAAGAGTTCATAGACGACAATGCCACTACA

CK 20

X73502

Forward
Reverse
Probe

TGCGAAGTCAGATTAAGGATGCT
CCACTGTTAGACGTATTCCTCTCTCA
CATACTTCAGTCTGAAGTCCTCAGCAGCCAGT

PSA

NM-001648

Forward
Reverse
Probe

CATTGAACCAGAGGAGTTCTTGAC
TCCAGCACACAGCATGAACTT
AACTTGCGCACACACGTCATTGGAA

HEP

AF144325

Forward
Reverse
Probe

TCGTGGACCTGGACTTCTTCA
ACAAGCCTCTGGCCAAGGTA
CCACGGACCCGCGGTTCCT
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Amplifications of an endogenous control (GAPDH or 18S) were performed to
standardize the amounts of sample RNAs added to reactions. Commercially available
primers and probes for the housekeeping genes, GAPDH and 18S, were obtained from
Applied Biosystems. The TaqMan One-Step RT-PCR Master Mix Reagents which
combine the key components into a master mix designed for one-step RT-PCR were
obtained from Applied Biosystems. The same universal thermal cycling parameters were
used for all quantitative TaqMan assays. The reverse transcription step was carried out at
48°C for 30 minutes. The polymerase (Amlitaq Gold) was activated at 95°C for 10
minutes. Forty cycles of RT-PCR were done, each consisting of 95°C for 15 seconds and
60°C for 1 minute.
Data Analyses
The levels of marker gene expression in tissue, blood and bone marrow samples, as
well as in Hs578T positive cell line (American Type Culture Collection), were quantitated.
Relative quantitation with data from the ABI PRISM 7700 Sequence Detection System
(SDS) was performed using the SDS 1.7 Software (Applied Biosystems). The initial SDS
software analysis of the acquired fluorescent data include normalization of the reporter dye
signal to an internal passive reference, calculation of the ∆Rn and Ct values, and standard
curve construction. Normalization was necessary to correct for fluorescent fluctuations due
to changes in concentration or volume. Normalization was accomplished by dividing the
emission intensity of the reporter dye by the emission intensity of the Passive Reference to
obtain a ratio defined as the Rn (normalized reporter) for a given reaction tube. The
Passive Reference was a dye included in the 10X TaqMan Buffer and did not participate in
the 5’-nuclease assay. ∆Rn reliably indicated the magnitude of the signal generated by the
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given set of PCR conditions. The value was calculated as the difference between the Rn+
value, the Rn of a reaction containing all components including the template, and the Rnvalue, the Rn value of an unreacted sample, as for example that obtained from a reaction
not containing template, a No Template Control. To ensure statistically high confidence
levels, at least three No Template Controls per microplate were used. The threshold cycle
or Ct value was the cycle at which a statistically significant increase in ∆Rn was first
detected, in other words, the increase in signal associated with an exponential growth of
PCR product.
Relative quantitations were performed using the standard curve method. Below is a
sample example of a standard curve for MAGE 3 and formulas used for calculations
(Figure 2).

MAGE-3 Standard Curve
28
y = -3.4607x + 21.176
R2 = 0.9928

Ct value

26

Series1

24

Linear (Series1)

22

20
-2

-1.5

-1

-0.5

0

log ng

Figure 2. MAGE 3 standard curve and quantitation formulas
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X = (Ct value –b)/ m
b = 21.176
m = -3.4607
input amount = 10^X

The construction of standard curves was based on the linear relationship between
the cycle threshold (Ct) and the log of concentration (ng) of a sample RNA. The input
amount was calculated by using m and b values, then was normalized against the
endogenous control (quantitation of an mRNA target normalized for differences in the
amount of total RNA added to each reaction). Subsequently, it was calibrated using the
Hs578Bst values (negative cell line from normal breast tissue).
Microarrays
Atlas Nylon Human Cell Interaction Arrays containing 265 genes encoding for
cell-cell interaction molecules were purchased from BD Biosciences, Clontech (Palo Alto,
California). The membranes also contained 9 housekeeping genes, such as ubiquitin C,
tubulin alpha 1, cytoplasmic beta-actin, etc, and 3 negative controls (M13 mp18(+) strand
DNA, lambda DNA, and pUC18 DNA). Atlas SpotLight Probe Labeling Kit (Clontech)
was used for probe labeling and SpotLight Chemiluminescent Hybridization and Detection
Kit (Clontech) was used for hybridization and detection procedures as specified by the
manufacturer. Briefly, probe mixtures were synthesized and directly labeled by reverse
transcribing the total RNA (extracted from 00716247Tln and 5062801Tln samples) using
the cDNA synthesis (CDS) Primer Mix and the SpotLight Labeling Kit which contained a
labeling mix with biotinylated dCTP. Labeled cDNAs were purified from unincorporated
biotin-labeled nucleotides and small cDNA fragments using the Atlas Nucleospin
Extraction Kit. Membranes were prehybridized at 42°C for 2 hours, then they were
hybridized with the biotin-labeled probes overnight at 42°C using the SpotLight
Chemiluminescent Hybridization and Detection Kit. After high stringency washes
hybridization patterns of probes were detected and signals were visualized both by
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exposing the membranes to X-ray films and by scanning them using the AlphaEaseFC
Imaging System equipment (FluorChem IS-8800, Alpha Innotech, San Leandro,
California).
Cloning and Spotting of Overexpressed Genes
Three of the overexpressed genes from microarrays (EMMPRIN_extracellular
matrix metalloproteinase inducer, DSH homolog 1-like; DVL1L1_dishevelled homolog 1like protein, and TIMP1_ tissue inhibitor of metalloproteinase 1) were cloned into the
pcDNA2.1 vector (Invitrogen, Carlsbad, California) for E. coli propagation and confirmed
by sequencing using T7 primer. The cloned fragments, about 500 base pairs each were
amplified by PCR. 1µl of each PCR product and negative controls (H2O, λ DNA, and
pUC19) were spotted in triplicate on nylon membranes (Zeta-Probe Membranes (Bio-Rad,
Herculaes, California). Membranes were placed in UV Stratalinker 2400 equipment
(Stratagene) to crosslink and immobilize the DNA samples. Membranes were
prehybridized at 42°C for 2 hours, then they were hybridized with the biotin-labeled
probes from 5062801Tln and 00716247Tln samples overnight at 42°C using the SpotLight
Chemiluminescent Hybridization and Detection Kit. X-ray pictures were taken.

41

RESULTS
Development of TaqMan Assays for Selected mRNA Tumor Markers
Detection and quantification of the relative expression levels of multiple tumor
mRNAs requires high quality, contamination-free RNA with a satisfactory concentration
for sensitive molecular methods such as RT-PCR. During the developmental stage of the
breast cancer project, multiple methods and equipment were used to purify RNA until
methodologies were developed to assure a high degree of reproducibility of real-time PCR
results. The best results were obtained when RNA was extracted using the Absolutely
RNA RT-PCR Miniprep Kit (Stratagene, La Jolla, California) specifically optimized for
RT-PCR incorporating effective on-column DNA removal specifically for RT-PCR
applications. This system simplifies the traditional guanidine thiocyanate method by using
a silica-based matrix in a spin-cup format. All the data presented here were derived from
RNA samples purified with the above mentioned methodology (see Materials and
Methods).
TaqMan real-time quantitative RT-PCR assays were developed for six mRNA
tumor markers: (I) MAGE 3 (melanoma antigen E 3); (II) HER2/NEU (human epidermal
growth factor receptor 2); (III) MGB 1 (mammoglobin 1); (IV) CK 20 (cytokeratin 20);
(V) PSA (prostate specific antigen); and (VI) HPR (heparanase). PCR primers and
TaqMan probes were designed through the use of Primer Express software and empirical
observations of the oligonucleotide sequences (see Materials and Methods).

In all

instances the targeted nucleotide sequence was less than 200 bases long. The expression
levels of the marker genes relative to standard curves of cell lines were calculated,
normalized against the endogenous control and calibrated to the negative breast cancer cell
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line Hs578Bst as detailed in Materials and Methods. Figure 3 shows a typical real-time
PCR amplification reaction as visualized and graphed by computer-assisted software in the
Perkin Elmer ABI PRISM 7700 Sequence Detection System. Typically, robust
amplifications of targets were obtained for both selected mRNA tumor markers as well as
endogenous controls (GAPDH or 18S).

Figure 3. Amplification plot of a real-time TaqMan RT-PCR experiment for MAGE 3 in
bone marrow samples

The tables below show the relative quantities for each of the six marker genes for
the individual tissue, blood and bone marrow samples from the breast cancer patients
(Tables 4; 5; 6; 7; 8; 9).
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Table 4. Relative quantities of MAGE 3 marker gene expression in tissue, blood and bone
marrow samples of breast cancer patients
Calibrated to Hs578Bst

Bone Marrow
Sample Name

Calibrated to Hs578Bst

5062801Tln

2964

5057331BMl

73800

00716247Tln

19200

713328BMl

0.004

00657403Tbts

1163

713328BMr

2090

00716247Tbtm

103944

313163BMr

295

4

5057331BMr

2400

5057331Tbtm

7010

05062801BMl

44200

05065155Tun

16218316

05062801BMr

1390000000

1
152

5061542BMr

27

5056311BMl

1680

053145BMr

2070000000000

5056311BMr

22500

5056242BMl

5780

053145BMl

4650000

5056242BMr

65300000

Tissue
Sample Name

0Tun

Hs578Bst
Hs578T
Blood
Sample Name

Calibrated to Hs578Bst

5062801BD

2

506322BD

0.2

5061542BD

28

657403BD

119

05065155BD

50

5057331BD

130

8/02/00BD

4261

Hs578Bst
Hs578T

1
0.03
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323496BMl

1394808925

313163BMl

157610

Hs578Bst
Hs578T

1
34827

Table 5. Relative quantities of HER2/NEU marker gene expression in tissue, blood and
bone marrow samples of breast cancer patients
Tissue
Sample Name

Bone Marrow
Sample Name

Calibrated to Hs578Bst

Calibrated to Hs578Bst

5062801Tln

308

713328BMl

894

00716247Tln

387

713328BMr

89

00657403Tbts

1

313163BMr

5

00716247Tbtm

62

5056311BMr

6

0Tun

0.4

053145BMl

8

5057331Tbtm

0.1

5056242BMr

1

05065155Tun

36

323496BMr

0.5

1
0.0002

323496BMl

2

313163BMl

4

Hs578Bst
Hs578T
Blood
Sample Name
5062801BD

0.001

506322BD

0.02

5061542BD

0.0004

657403BD

0.06

05065155BD

0.01

5057331BD

0.009

8/02/00BD

14

00408233BD
Hs578Bst
Hs578T

Hs578Bst
Hs578T

Calibrated to Hs578Bst

4670
1
0.0002
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1
0.0002

Table 6. Relative quantities of MGB 1 marker gene expression in tissue, blood and bone
marrow samples of breast cancer patients
Tissue
Sample Name

Calibrated to Hs578Bst

Bone Marrow
Sample Name

Calibrated to Hs578Bst

5062801Tln

16556

5057331BMl

4950582

5061542Tln

2332

713328BMl

105614

00657403Tbts

2350

713328BMr

66677

00716247Tbtm

9906

313163BMr

2231328

0Tun

7088

5057331BMr

45462

5057331Tbtm

4544

05062801BMl

467876522709

05065155Tun

5351

5061542BMr

4324264

1
1066325

5056311BMl

11400000000000

053145BMr

1427667908

5056311BMr

5717382771

5056242BMl

26256465

053145BMl

4759889

5056242BMr

313464

323496BMr

80100000000000

323496BMl

16416569953

313163BMl

1411368915

5053504BMr

4733029432

05063173BMr

320991

05063173BMl

781037

Hs578Bst
Hs578T

Blood
Sample Name

Calibrated to Hs578Bst

5062801BD

33071

506322BD

4

5061542BD

2

657403BD
05065155BD

1039101
5095152568

5057331BD

46029599

8/02/00BD

0.04

Hs578Bst
Hs578T

1
1.7

Hs578Bst
Hs578T
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1
1.7

Table 7. Relative quantities of CK 20 marker gene expression in tissue, blood and bone
marrow samples of breast cancer patients
Tissue
Sample Name

Calibrated to Hs578Bst

Bone Marrow
Sample Name

Calibrated to Hs578Bst

5062801Tln

4889029

5057331BMl

2167966

00716247Tln

97564

713328BMl

1428841363

5061542Tln

70451855

713328BMr

41930002922

00657403Tbts

13429158

313163BMr

71726552

00716247Tbtm

4214750

5057331BMr

626636

33008

05062801BMl

6526575

5057331Tbtm

17200073

05062801BMr

70172857165

00497241Tbtm

1470000000000

5061542BMr

31445

05071355Tbtm

3182792

5056311BMl

1086430

05065155Tun

6601348

053145BMr

715024

1
2038

5056311BMr

9705186

0Tun

Hs578Bst
Hs578T
Blood
Sample Name

367204206

506322BD

845000000000

657403BD

317000000000

05065155BD

45964232658

5057331BD

24330876750

8/02/00BD

12550537

Hs578Bst
Hs578T

6667135148

5056242BMr

765139883

323496BMr

302212

323496BMl

62909073

313163BMl

5371481

5053504BMr

27545799

05063173BMr

11527

05063173BMl

38606

Hs578Bst
Hs578T

1
2038

Calibrated to Hs578Bst

5062801BD

00408233BD

053145BMl

212000000000
1
2038
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Table 8. Relative quantities of PSA marker gene expression in tissue, blood and bone
marrow samples of breast cancer patients
Tissue
Sample Name

Calibrated to Hs578Bst

Bone Marrow
Sample Name

Calibrated to Hs578Bst

5062801Tln

194413963

5057331BMl

50256

00716247Tln

10367891

713328BMl

15377518

5061542Tln

42253609027

713328BMr

9839563168

00657403Tbts

45996208

313163BMr

901129

00716247Tbtm

308727899

5057331BMr

91037

2994075

05062801BMl

2090891

5057331Tbtm

9943595532

05062801BMr

3619288989

00497241Tbtm

203934000000000

5061542BMr

8884

05071355Tbtm

132404068

5056311BMl

40619

05065155Tun

549137203

053145BMr

8497

1
552304

5056311BMr

142148

323496BMr

2775

323496BMl

68251876

313163BMl

2559204842

0Tun

Hs578Bst
Hs578T
Blood
Sample Name

Calibrated to Hs578Bst

5062801BD

24515292365

506322BD

2281920000000000

657403BD

50809400000000

05065155BD

324658000000000

5057331BD

570793000000000

8/02/00BD

834879459

00408233BD
Hs578Bst
Hs578T

5053504BMr

4099839

05063173BMr

29517

05063173BMl

1858

Hs578Bst
Hs578T

229069000000000
1
552304
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1
552304

Table 9. Relative quantities of HPR marker gene expression in tissue, blood and bone
marrow samples of breast cancer patients
Tissue
Sample Name

Calibrated to Hs578Bst

Bone Marrow
Sample Name

Calibrated to Hs578Bst

00716247Tln

311249

5057331BMl

11870

5061542Tln

127561335

713328BMl

2

00657403Tbts

61928266888

713328BMr

118

00716247Tbtm

379353478

313163BMr

21

94145598765

5057331BMr

1

5057331Tbtm

557200971

05062801BMl

308

05065155Tun

29940940539

05062801BMr

0.2

00497241Tbtm

3131

5061542BMr

12

05071355Tbtm

255363302

5056311BMl

67

42578906Ttm

9321463717

053145BMr

407

1
29

5056311BMr

152

5056242BMl

130

053145BMl

1524

0Tun

Hs578Bst
Hs578T
Blood
Sample Name

Calibrated to Hs578Bst

5062801BD

1274055

506322BD

56447

657403BD

132809939

05065155BD

171114

5057331BD

406816

8/02/00BD

735192

00408233BD

1525775

05077954BD

224575511

42578906BD

3847460

Hs578Bst
Hs578T

5056242BMr

0.3

323496BMr

1423

323496BMl

139909

313163BMl

470

5053504BMr

667198

05063173BMr

41

05063173BMl

74968

42578906BMr

17810643

42578906BMl

203346

Hs578Bst
Hs578T

1
13

49

1
37

Only three of the patients had all three types of samples (tissue, blood, and bone
marrow) available. Table 10 shows the results of MAGE 3 relative expression for that
three breast cancer patients with available tissue, blood, and bone marrow samples.

Table 10. MAGE 3 expression in tissue, blood, and bone marrow samples of patients
known to have breast cancer
Sample number and types

Relative expression of MAGE 3

5057331
breast tumor tissue
blood
bone marrow (r)*
bone marrow (l)*

high
high
high
very high

5062801
lymph node tissue
blood
bone marrow (r)
bone marrow (l)

high
low
very high
very high

5061542
lymph node tissue **
blood
bone marrow (r)

high
high

* r and l – right or left bone marrow aspirates
** no available sample

Selection of Additional mRNA Tumor Marker Genes through the Use of
Micro-arrays Spotted With Genes Involved in Cell-cell Interactions
A subset of the initial set of tumor markers represented cell surface expressed
protein and glycoprotein antigens. Therefore, it was of interest to test additional cell
surface expressed antigens as potential mRNA tumor markers.

For this purpose,

commercially available microarrays containing genes coding for proteins involved in cellcell interactions were tested using labeled mRNA from specific tumor samples. Two tissue
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samples, which had high relative expression levels of MAGE 3 and HER2/NEU genes
were used in the microarray experiments with Atlas Nylon Human Cell Interaction Arrays
containing 265 genes (Clontech, Inc). The arrays contained multiple housekeeping genes
serving as internal controls, as well as genes serving as negative controls (see Materials
and Methods). Biotin-labeled probes were prepared from 00716247Tln and 5062801Tln
lymph node samples of two breast cancer patients. Figure 4A shows the photograph of the
microarrays after hybridization using labeled cDNA probe obtained from the 0071624Tln
tumor sample. Figure 4B shows the X-ray picture of the microarray hybridized with a
probe made from the 5062801Tln sample. Both figures show a number of relatively
overexpressed genes as dense dots pointed by arrows.
A

Figure 4. Microarrays hybridized with lymph node samples. A. cDNA microarray was
hybridized with biotin-labeled probe prepared from RNA of 0071624Tln sample. B. cDNA
microarray was hybridized with biotin-labeled probe prepared from RNA of 5062801Tln
sample. The arrows indicate the relatively overexpressed genes. The locations of
overexpressed EMMPRIN, DVL1L1, and TIMP 1 genes are indicated by green, blue, and
red arrows respectively (full names of the genes in Table 10) (Figure continued)
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B
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The top six of the highly overexpressed genes discovered as a result of these
microarray experiments are listed in table 11. These six genes were found to be
overexpressed in both microarray hybridization experiments.
Table 11. The full and abbreviated names of some genes highly overexpressed on both
microarrays
GenBank
Accession #
L20471

Gene/protein name

Gene/protein classification

basigin (BSG); leukocyte activation antigen M6;
collagenase stimulatory factor; extracellular
matrix metalloproteinase inducer (EMMPRIN);
5F7; CD147 antigen
dishevelled homolog 1-like protein (DSH
homolog 1-like; DVL1L1)

Other Enzymes Involved in Protein
Turnover
Cell Surface Antigens

M63928

tumor necrosis factor receptor superfamily
member 7 (TNFRSF7); CD27L antigen receptor

D13866

alpha 1 catenin (CTNNA1); cadherin-associated
protein

Death Receptors
Growth Factor & Chemokine Receptors
Other Receptors (by Activities)
Cell Surface Antigens
Matrix Adhesion Receptors

X03124

tissue inhibitor of metalloproteinase 1 (TIMP1);
erythroid potentiating activity protein (EPA);
collagenase inhibitor (CLGI)
CD4 antigen; T-cell surface glycoprotein
T4/leu3

U46461

M12807

Other Intracellular Transducers,
Effectors and Modulators

Protease Inhibitors
Cell Surface Antigens

Production of In-house Macroarrays for Selected Genes
As part of these feasibility studies for assessing the relative potential of diagnostic
procedures for the detection of mRNA tumor markers, it was essential to assess whether
custom made macro and microarrays could be developed. For this purpose, three genes,
which were highly overexpressed in both hybridization experiments were chosen for
custom spotting on nylon membranes. A target nucleotide sequence of approximately 500
bases from each gene was amplified using specific PCR primer sets, cloned into plasmid
vectors for E. coli propagation and confirmed by DNA sequencing. Individual gene
segments were re-amplified from their respective plasmids and spotted onto nylon
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membranes (see Materials and Methods). The three genes selected for these experiments
are shown on Table 12.
Table 12. The full and abbreviated names of three overexpressed genes selected for
spotting on nylon membranes
GenBank
Accession #

Gene/protein name

Gene/protein classification

L20471

basigin (BSG); leukocyte activation antigen M6;
collagenase stimulatory factor; extracellular matrix
metalloproteinase inducer (EMMPRIN); 5F7;
CD147 antigen

Other Enzymes Involved in
Protein Turnover,
Cell Surface Antigens

U46461

dishevelled homolog 1-like protein (DSH homolog
1-like; DVL1L1)

X03124

tissue inhibitor of metalloproteinase 1 (TIMP1);
erythroid potentiating activity protein (EPA);
collagenase inhibitor (CLGI)

Other Intracellular
Transducers, Effectors and
Modulators
Protease Inhibitors

Genes were spotted in triplicate onto nylon membranes and hybridized with biotinlabeled probes prepared from 00716247Tln and 5062801Tln lymph node tumor samples.
Figure 5 shows the hybridization pattern of the arrays containing the three genes as well as
control DNA samples. The selected overexpressed genes appeared as triplets of densestained dots. Negative controls did not show any hybridization signals. These experiments
verified relative overexpression of EMMPRIN, DVL1L1, and TIMP 1 genes in tumor
samples of breast cancer patients.
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Figure 5. Hybridization pattern of three overexpressed genes (EMMPRIN, DVL1L1, and
TIMP 1) and negative controls spotted on nylon membranes as triplets and hybridized with
00716247Tln (left) and 5062801Tln (right) lymph node samples
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DISCUSSION AND CONCLUSIONS
The overall goal of these investigations was to assess the potential of real-time
quantitative RT-PCR based on fluorescent TaqMan methodology and microarray analyses
as tools for the detection and quantification of multiple mRNA tumor markers of breast
cancer. Previous work (81-84) showed the potential of detecting specific mRNA markers
by RT-PCR and Southern Blot analyses of breast cancer and melanoma samples obtained
from patients. It was concluded that the multiple-marker RT-PCR and Southern blot assays
improve the occult metastases detection in patient samples when compared to conventional
hematoxylin and eosin staining and immunohistochemistry analysis, which alone
underestimate the true incidence of metastases.
TaqMan Assays
Newer molecular methodologies such as real-time TaqMan RT-PCR and cDNA
microarrays have been used in these feasibility studies for assessing the relative potential
of diagnostic procedures for the detection of mRNA tumor markers in breast cancer patient
samples.
To develop a sensitive detection assay for selected mRNA tumor markers in tissue,
blood, and bone marrow samples of breast cancer patients, a variety of RNA extraction
methods were attempted. The best method of RNA extraction included the use of a
commercially available extraction kit (Absolutely RNA RT-PCR Miniprep Kit)
specifically optimized for RT-PCR. The Absolutely RNA RT-PCR kit is stringently
qualified for RT-PCR incorporating effective on-column DNA removal specifically for
RT-PCR applications. The Absolutely RNA system simplifies the traditional guanidine
thiocyanate method by using a silica-based matrix in a spin-cup format. RNA was

56

extracted from all the samples using the mentioned kit. Six mRNA tumor markers were
selected and real-time quantitative RT-PCR TaqMan assays were developed and applied to
detect them as well as quantify their relative expression levels in tissue, blood, and bone
marrow samples. The selected markers were: (I) MAGE 3 (melanoma antigen E 3); (II)
HER2/NEU (human epidermal growth factor receptor 2); (III) MGB 1 (mammoglobin 1),
(IV) CK 20 (cytokeratin 20); (V) PSA (prostate specific antigen); (VI) HEP (heparanase).
Among these six markers, MAGE 3 was the prevalent mRNA tumor marker and was
reliably amplified from different samples of patients confirmed with breast cancer as well
as from some blood samples. 18S (18S ribosomal RNA) and GAPDH (catalytic enzyme
involved in glycolysis and called glyceraldehyde-3-phosphate dehydrogenase) internal
standards were used as endogenous references (controls). Substantial problems were
experienced obtaining reasonable Ct values for the endogenous control GAPDH. Multiple
comparisons of experimental data suggested that 18S was a better endogenous control, thus
GAPDH was used only for the initial runs that were testing the HER2/NEU marker and
18S was used in TaqMan assays for the remaining five markers.
Ideally, negative controls should be obtained from patients and the data from these
negative samples should be used in quantitations. Because of substantial difficulties in
obtaining appropriate negative controls, attempts were made to derive meaningful data by
comparing clinical samples to a negative cell line derived from breast tissue. A similar cell
line, obtained from breast tumor tissue of the same patient was also available as a positive
control. Many of the mRNA markers could be efficiently amplified from tissue, bone
marrow, and blood samples of patients known to suffer with metastatic breast cancer (see
Materials and Methods, Table 2).
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The results from TaqMan assays showed that some of the samples obtained from
the same patient with breast cancer had a good correlation for high expressions of some
markers. For example, MAGE 3 was amplified from tumor tissue, blood, and bone marrow
of patient number 5057331 (see Results, Table 4). It had high expression values in all the
three samples compared to negative cell line values. It was also overexpressed and was
amplified from blood and bone marrow of patient number 5061542 (28- and 27-fold
overexpression, respectively). Unfortunately, the lymph node tissue sample of this patient
was depleted in earlier experiments, thus it couldn’t be tested for MAGE 3 gene
expression. MGB1 had high expression values in lymph node and bone marrow of patient
number 5061542 (2332- and 4324264-fold overexpression, respectively), although not in
blood of the same patient (only 2-fold overexpression) (see Results, Table 6), which
probably means that either there were no circulating tumor cells in the blood, or the marker
MGB1 couldn’t be detected in circulating cancer cells. Table 10 shows the results of
MAGE 3 relative expression for breast cancer patients with available tissue, blood and
bone marrow samples. There were only these three patients for whom tissue, blood, and
bone marrow samples were available. MAGE 3 was readily amplified from all of the three
mentioned patient samples. 10-fold and higher overexpressions were considered high
expressions, less than that were considered low. More than 10,000-fold overexpressions
were considered as very high expressions (see also Table 4). Generally, MAGE 3 was
overexpressed in all samples obtained from the three patients shown in Table 10, with the
exception of one blood sample, which showed a low expression value for MAGE 3 leading
to the conclusion that, most probably, there were no circulating cancer cells in this
patient’s blood.
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Overall, the results showed very high expression values for most of the markers.
Some of these values were unreasonably high. For example, MAGE 3 was 207x 1010-fold
overexpressed in right bone marrow aspirate of patient number 053145BMr (see Results,
Table 4, Bone Marrow), MGB 1 was 801x1011-fold overexpressed in right bone marrow
aspirate of patient number 323496 (see Results, Table 6, Bone Marrow), CK 20 was
845x109 times overexpressed in blood sample of patient number 506322 and 147x1010
times overexpressed in breast tumor sample of patient number 00497241 compared to
negative cell line (see Results, Table 7), etc. These results indicate that calibrations to a
negative cell line control produced artificially higher values of certain marker potentially
because cell lines have very low amounts of these mRNA tumor markers. The absence of
reliable negative samples from patients as well as the limited number of samples obtained
were major problems, which prevented any statistical determination of the relative
importance of the developed real-time PCR diagnostics. Real-time PCR may be a highly
efficient diagnostic tool if positive and negative tissue samples can be obtained from the
same patient, and if with positive blood and bone marrow samples obtained from breast
cancer patients negative blood and bone marrow samples could be obtained from healthy
individuals. Similarly, real-time PCR may be effectively applied to follow the disease
progression and response to therapy of an individual patient.
PCR methods have been shown to be superior in detecting minute amounts of
tumor cells compared to other methods. The extreme sensitivity implies that false positive
test results are likely to occur. The ultimate choice of molecular marker(s) and
methodology to use in a clinical setting will be determined by its sensitivity and potential
to discriminate between true micrometastases and background noise (117). The clinical
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value of molecular detection of micrometastases will be detemined by its potential to
increase prognostication of individual patients and by its predictive value of response to
adjuvant treatment. For these purposes large trials are necessary in which the assay used to
detect micrometastases gives unequivocal, reproducible results and is easy to use. For
breast cancer, there is still a need for a cancer-specific marker which reliably can detect
micrometastatic disease. Most probably a combination of carefully selected markers must
be used to ensure a high detection rate. RT-PCR analysis is a particularly sensitive
technique for the purpose of detecting occult breast cancer cells in the lymph nodes, blood,
and bone marrow of breast cancer patients (38-40; 118).
Microarrays
The advent of microarray technology has revolutionized the molecular profiling of disease
tissues and tumors. It is one of the most promising and powerful methodologies in
molecular oncology. This newer technology was used to test additional molecules as
potential mRNA tumor markers for breast cancer diagnostics. Cell interaction cDNA atlas
nylon arrays were selected to pursue the goal of discovering additional markers, such as
adhesion molecules, extracellular matrix proteins, etc. involved in cell to cell interactions.
The basic assumption here was that cell surface proteins involved in cellular adhesion and
cell-to-cell communication may be overexpressed in breast cancer samples. In this
feasibility study, multiple overexpressed genes were identified from two lymph node
samples of breast cancer patients as new potential mRNA tumor markers for diagnosis of
breast cancer (see Results). Interestingly, genes for extracellular matrix metalloproteinase
inducer (EMMPRIN), dishevelled homolog 1-like protein (DVL1L1), tissue inhibitor of
metalloproteinase 1 (TIMP1), alpha 1 catenin (CTNNA1), tumor necrosis factor receptor
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superfamily member 7 (TNFRSF7), and some other cell interaction molecules were highly
overexpressed in the both lymph node samples of the breast cancer patients. Specifically,
TIMP1 and EMMPRIN have been shown by others to be overexpressed in breast and some
other cancers (119-123). There are many gaps in understanding the molecular basis of
cancer metastasis formation, but it was shown that both EMMPRIN (inducer of MMPs)
and TIMP-1 (inhibitor of MMPs) can be overexpressed in cancer patients playing crucial
roles in cancer progression and predicting a poor prognosis. Invasion and metastasis of
tumor cells involves the degradation of the basement membrane, caused by proteases
derived from the tumor or adjacent normal cells or tumor-infiltrating immune cells. A class
of proteases implicated in this process is the matrix metalloproteinases (MMPs), which are
a family of zinc-dependent neutral endopeptidases. Aberrant MMP activity in tumor cells
and surrounding stromal tissue is implicated in tumor progression, invasion, metastasis and
angiogenesis. The activity of MMPs in the extracellular space is controlled by a family of
specific inhibitors, the TIMPs. EMMPRIN is prominently displayed in human cancer
tissue and plays an important role in cancer progression by increasing synthesis of MMPs
(122; 123). EMMPRIN plays a role in tumor invasion, metastasis, and neoangiogenesis by
stimulating extracellular matrix remodeling around tumor cell clusters, stroma, and blood
vessels. The latest data suggest that dishevelled proteins organize dynamic subcellular
signaling complexes functioning in signal transduction through Wnt pathways. Abnormal
disheveled protein and Wnt signaling can cause a variety of diseases as well as cancer
(reviewed by Wharton KA Jr. (124).
From the initial experiments, three genes, which were highly overexpressed in both
hybridization experiments, were selected for further investigations including custom
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spotting on nylon membranes. These experiments revealed that diagnostic macro- and
microarrays can be produced for the rapid screening of biological samples for the
overexpression of mRNA tumor markers. These experiments utilized PCR-derived gene
fragments of about 500 base pairs. Alternatively, multiple synthetic oligonucleotides
representing different parts of each target gene can be spotted onto nitrocellulose or glass
slides. Rapid synthesis of oligonucleotides will enable the spotting of many gene targets
onto arrays enhancing the potential for obtaining clinical relevant data. Finally, initial
screening by microarrays can be followed by real-time PCR validation of individual
mRNA results.
The present investigations constituted feasibility studies for the development of
reagents and protocols for the use of TaqMan and microarray assays. Overall, it was
concluded that such assays can be easily designed and implemented for the screening of
large number of clinical specimens. TaqMan RT-PCR is an extremely sensitive technique.
That’s why the presence of carefully selected controls, high purity RNA from samples, and
other important parameters of TaqMan runs are of great importance. The TaqMan assays
developed for this project can be used for the detection of mRNA tumor markers in various
samples from breast cancer patients and probably will have more significant results when
used for bigger sized samples with negative controls taken from same patients’ not
diseased tissues or from healthy individuals. The set, rather than a single marker gene, may
significantly decrease the likelihood of false positive results.
Microarray experiments revealed that custom arrays can be easily produced
incorporating many potential mRNA tumor markers.

Microarrays have a number of

advantages over TaqMan assays, especially when many clinical samples are to be
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screened. In addition, microarrays can incorporate multiple positive and negative controls
as well as multiples of the same sample at different locations of the array to ensure
reproducibility and statistical significance. Ideally, initial screening of biological samples
could be done by microarray analysis and individual positive samples could be confirmed
by additional tests using TaqMan assays.
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